InMed Pharmaceuticals (INM)
(Real Time Quote from BATS)
$0.28 USD
0.00 (0.61%)
Updated Sep 19, 2024 12:50 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
InMed Pharmaceuticals Inc. [INM]
Reports for Purchase
Showing records 1 - 20 ( 31 total )
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
THCV launch expands rare cannabinoids portfolio
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
Health and wellness product launches
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
Health and wellness product launches
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
FY3Q22 Recap - Waiting for Visibility into Commercial Ops
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
Notable launches of high-value rare cannabinoids
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
Generating commercial sales of CBC and CBT
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
Charging After Pharmaceutical-Grade Cannabinoids; Initiating at Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: InMed Pharmaceuticals Inc.
Industry: Medical - Drugs
FY1Q22 Recap - Pipeline on Track with Near-term Revenues
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S